Cargando…

Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection

INTRODUCTION: Most of the drugs associations that have been used to treat patients with SARS-CoV-2 infection increase the risk of prolongation of the corrected QT interval (QTc). OBJECTIVE: To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moschini, Luigi, Loffi, Marco, Regazzoni, Valentina, Di Tano, Giuseppe, Gherbesi, Elisa, Danzi, Gian Battista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364290/ https://www.ncbi.nlm.nih.gov/pubmed/32676695 http://dx.doi.org/10.1007/s00380-020-01671-4

Ejemplares similares

Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

QT interval prolongation with hydroxychloroquine plus azithromycin
Publicado: (2020)

Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection
por: Loffi, Marco, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report
Publicado: (2020)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)

Inhibidores del sistema renina-angiotensina y pronóstico durante tratamiento con hidroxicloroquina en pacientes hospitalizados por neumonía por COVID-19
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen
por: Bernardini, Andrea, et al.
Publicado: (2021)

System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation
por: Khan, Abdul Arif, et al.
Publicado: (2020)

THE EFFECT OF TREATMENT WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ON THE CORRECTED QT INTERVAL IN PATIENTS WITH COVID-19
por: Batemarco, Thomas, et al.
Publicado: (2022)

Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021)

Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring
por: Ramireddy, Archana, et al.
Publicado: (2020)

Prolonged QT Interval in a Patient With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin
por: Anupama, B K, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolonged QT interval during off label use: case report
Publicado: (2021)

Severe COVID-19 Pneumonia and Very Late Stent Thrombosis: a Trigger or Innocent Bystander?
por: Galeazzi, Gian Luca, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Complete atrioventricular-block, torsades-de-pointes and QT-interval-prolongation following off label use: 2 case reports
Publicado: (2020)

Azithromycin/hydroxychloroquine interaction: QT interval prolongation following off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: Corrected QT-interval prolongation following off label use: case report
Publicado: (2020)

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin
por: Chorin, Ehud, et al.
Publicado: (2020)

Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection
por: Voisin, Olivier, et al.
Publicado: (2020)

QT interval monitoring for inpatient treated with hydroxychloroquine/azithromycin association in the context of SARS-CoV-2 pandemic
por: Bun, S., et al.
Publicado: (2021)

Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
por: Cipriani, Alberto, et al.
Publicado: (2020)

Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
por: Eftekhar, Seyed Parsa, et al.
Publicado: (2021)

Effects of hydroxychloroquine treatment on QT interval
por: Hooks, Matthew, et al.
Publicado: (2020)

Hydroxychloroquine-associated QT interval prolongation
Publicado: (2020)

Azithromycin: QT interval prolongation: case report
Publicado: (2021)

The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
por: Bakhshaliyev, Nijad, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Lengthening of the QT interval, bradycardia and atrioventricular block following an off-label use: case report
Publicado: (2020)

Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19
por: O’Connell, Thomas F., et al.
Publicado: (2021)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2021)

QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019
por: Tuncer, Tunc, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: QT-interval prolongation and polymorphic ventricular tachycardia arrest due to off-label use: 2 case reports
Publicado: (2021)

Azithromycin/hydroxychloroquine: QT prolongation following off label use: case report
Publicado: (2022)

Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation
por: Di Tano, Giuseppe, et al.
Publicado: (2021)

TCT CONNECT-217 Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval
por: Al-Sadawi, Mohammed, et al.
Publicado: (2020)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o6adqpd6h7dip6cesmcrq5ouir